

UNITED STATES PATENT AND TRADEMARK OFFICE

(12) CERTIFICATE EXTENDING PATENT TERM  
UNDER 35 U.S.C. § 156

(68) PATENT NO. : 8,008,309  
(45) ISSUED : August 30, 2011  
(75) INVENTOR : Lee Honigberg et al.  
(73) PATENT OWNER : Pharmacyclics, LLC  
(95) PRODUCT : IMBRUVICA® (ibrutinib)

This is to certify that an application under 35 U.S.C. § 156 has been filed in the United States Patent and Trademark Office, requesting extension of the term of U.S. Patent No. 8,008,309 based upon the regulatory review of the product IMBRUVICA® (ibrutinib) by the Food and Drug Administration. According to United States Patent and Trademark Office records, the original expiration date of the patent as of the date of issuance of this certificate is December 28, 2026. Because it appears that the requirements of the law have been met, this certificate extends the term of the patent for the period of

(94) 320 days

subject to the payment of maintenance fees as provided by law, with all rights pertaining thereto as provided by 35 U.S.C. § 156.



I have caused the seal of the United States Patent and Trademark Office to be affixed this 13th day of August 2020.

A handwritten signature in cursive script, reading "Andrei Iancu".

Andrei Iancu  
Under Secretary of Commerce for Intellectual Property and  
Director of the United States Patent and Trademark Office